Introduction

The Indian pharmaceutical industry has always played a significant role in the global healthcare ecosystem. From being the largest supplier of generic medicines to becoming a hub for active pharmaceutical ingredient (API) manufacturing, India’s pharma sector has consistently shown resilience and growth. In recent months, pharma stocks in India have been buzzing with increased investor interest. But what’s driving this momentum? And which are the best pharma stocks to buy now? Let’s dive deep into the reasons behind the rise and explore the top opportunities in the pharma sector.

India’s Growing Pharma Dominance

India is the world’s third-largest producer of pharmaceuticals by volume and the 14th largest by value. The country supplies over 20% of global generic medicines and exports to more than 200 countries. The increasing demand for affordable healthcare solutions, both domestically and internationally, is driving the growth of pharma stocks in India.

Key Statistics:

• Exports worth over ₹2.07 lakh crore in FY2024
• Over 10,500 manufacturing units
• Leader in vaccine and generic drug production

Key Drivers Behind the Pharma Stock Rally

A. Strong Export Performance

Indian pharma companies have expanded aggressively into regulated markets like the US, EU, and Japan. The demand for generics continues to grow, and Indian companies are well-positioned to meet it.

Update from April 2025: A key reason for the recent jump in pharma stocks in India is former U.S. President Donald Trump’s proposal of reciprocal tariffs on nations with high import duties. However, India’s pharmaceutical sector will likely be exempt from this policy. This exemption has boosted investor sentiment significantly, signalling continued access to the lucrative US market for Indian exporters like Cipla, Dr. Reddy’s, and Glenmark Pharma. This development further solidifies the outlook for pharma sector stocks.

B. China+1 Strategy

Global pharmaceutical companies are diversifying their supply chains away from China. This has led to a significant push for Indian API manufacturers and contract research organisations (CROs), favouring small-cap pharma stocks focused on raw material and R&D supply.

C. Government Initiatives & PLI Scheme

The Indian government’s Production Linked Incentive (PLI) scheme supports domestic manufacturing of APIs, KSMs (key starting materials), and drug intermediates, benefiting many pharma sector stocks and Nifty Pharma index stocks.

D. Rising Healthcare Awareness & Spending

Post-COVID, there’s a growing emphasis on preventive healthcare, wellness, and increased access to medicines, which has driven interest in both best pharma stocks to buy now and penny stocks in the pharma sector.

You may also want to know what is Market Sentiment

Nifty Pharma Index Stocks List (Major Players)

Best Stock in Pharma Sector to Buy in 2025

1. Sun Pharma

About: Sun Pharmaceutical Industries Ltd is involved in the manufacturing, development, and marketing of a broad portfolio of branded and generic formulations, as well as Active Pharmaceutical Ingredients (APIs). Along with its subsidiaries, the company operates multiple manufacturing facilities worldwide and carries out trading and other related activities across global markets.

India’s largest pharma company and a global leader in speciality generics and formulations. Strong pipeline and M&A-led growth.

Market cap: ₹ 4,10,130 Cr.

Pros: 

• The company has reduced debt.
• The company is almost debt-free.
• The company has delivered good profit growth of 23.4% CAGR over the last 5 years
• The company has been maintaining a healthy dividend payout of 46.6%

2. Cipla

About: Focuses on respiratory, anti-retroviral, and chronic therapies. Increasing its US generics and domestic branded business. The company expects a growth of ~20% till 2030 and aims to be the 2nd Largest Pharma company in the Rx Market in India. It aims to be the largest in SAGA and the 2nd largest in North America.

The Co. has produced 200+ generics and complex APIs supplied to 62 countries worldwide. It continues to be a preferred partner to many large generic pharmaceutical co.s. The API business has also made efforts to de-risk the supply chain for Cipla’s focus APIs, by shifting to indigenous suppliers for key starting materials (KSM) and intermediates. It has a robust pipeline of over 75+ APIs across regulated markets in various stages of development.

Market cap: ₹ 1,14,298 Cr

Pros: 

• The company has reduced debt.
• The company is almost debt-free.
• The company has delivered good profit growth of 25.1% CAGR over the last 5 years
• The company has been maintaining a healthy dividend payout of 22.0%

3. Divi’s Laboratories

About: Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API’s, Intermediates, and Nutraceutical ingredients. The company manufactures Generic Active pharmaceutical ingredients, Custom synthesis of APIs & Intermediates, along with Nutraceuticals for the Global Pharmaceutical & Nutraceutical industry. A global leader in APIs and custom synthesis, known for high margins and zero-debt status.

Market cap: ₹ 1,45,552 Cr.

Pros: 

• The company is almost debt-free.
• The company has been maintaining a healthy dividend payout of 40.1%

4. Dr. Reddy’s Laboratories

About: Dr. Reddy’s Laboratories Ltd is a leading India-based pharmaceutical company that offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars, and differentiated formulations. Strong presence in the US and emerging markets. Focus on complex generics and biosimilars. The company is increasing its focus on limited competition niche products, injectables, and biosimilars, which are expected to boost its revenues and profitability in the medium term.

Market cap: ₹ 92,620 Cr.

Pros: 

• The company has delivered good profit growth of 24.4% CAGR over the last 5 years.

5. Mankind Pharma Ltd

About: Incorporated in 1995, Mankind Pharma Limited is engaged in the development, manufacturing, and marketing of pharmaceutical formulations across a range of acute and chronic therapeutic segments, along with a diverse portfolio of consumer healthcare products. Co. has 42 Products under its US Portfolio. It has launched 1 new product in Q3FY25 and four new products in 9MFY25.

Market cap: ₹ 1,01,131 Cr.

Pros: 

• The company is almost debt-free.
• The company’s working capital requirements have reduced from 44.9 days to 35.4 days

Small Cap Pharma Stocks to Watch

These companies offer higher growth potential with relatively lower valuations:

1. Laurus Labs:

About: Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company with global leadership. API and formulation player with a strong export profile.

Position in select Active Pharmaceutical Ingredients (APIs), including anti-retroviral, oncology drugs (including Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing.

Laurus employs 6,500+ people, including 10,50+ scientists, at more than 11 facilities approved by global agencies such as the USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA, etc.

Market cap: ₹ 30,977 Cr.

Pros:

• The company has been maintaining a healthy dividend payout of 17.8%

2. Suven Pharmaceuticals

About: Hyderabad-based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing, we are committed to providing customers with products that fulfil customer needs and expectations in CDMO (contract development & manufacturing).

Market cap: ₹ 27,697 Cr.

Pros: 

• The company has reduced debt.
• The company is almost debt-free.
• The company has a good return on equity (ROE) track record: 3 Years ROE 21.9%

3. Marksans Pharma

About: Marksans Pharma is engaged in the formulation of pharmaceutical products. Rising profitability and global OTC presence.

Market cap: ₹ 9,366 Cr.

Pros:

•  The company is almost debt-free.

4. Neuland Labs:

About: Neuland Laboratories is engaged in manufacturing and selling bulk drugs, catering to both domestic and international markets. It specialises in complex APIs and peptides. Prime APIs segment comprises ~15 mature large-volume APIs in a highly competitive market.

Market cap: ₹ 14,676 Cr.

Pros:

• The company is almost debt-free.
• The company has delivered good profit growth of 78.6% CAGR over the last 5 years

Best Pharma Penny Stocks in India

Penny stocks are under ₹100 and come with high risk-reward potential. Here are some with momentum:

1. Morepen Laboratories Ltd

About: Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing, and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products

Market cap: ₹ 2,699 Cr.

Pros: 

• The company is almost debt-free.

2. IOL Chemicals

About: IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export markets.

Market cap: ₹ 1,817 Cr.

Pros: 

• The company is almost debt-free.
• Stock is trading at 1.10 times its book value
• The company has been maintaining a healthy dividend payout of 17.5%
• Promoter holding has increased by 4.43% over the last quarter.

3. Dishman Carbogen Amcis Ltd

About: Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals, and disinfectants with presence in Switzerland, UK, Europe, China, and other countries.

Market cap: ₹ 3,266 Cr.

Pros: 

• Stock is trading at 0.57 times its book value

Caution: Penny stocks in the pharma sector are volatile. Investors should research thoroughly and monitor regulatory news.

Sectoral Tailwinds for Indian Pharma

India’s pharmaceutical sector is poised for long-term growth, not just because of traditional strengths like generics and exports but due to emerging tailwinds that are reshaping the industry landscape. Here are some key growth accelerators:

A. Biotech and Biosimilars Growth

The next big pharma wave is in biologics and biosimilars, complex drugs derived from living organisms, used to treat chronic diseases like cancer, diabetes, and autoimmune disorders.

• Why it matters: Unlike generics, biosimilars are difficult to manufacture, offering higher margins and longer product life cycles.
• Indian edge: Indian pharma giants like Biocon, Dr. Reddy’s, and Lupin are heavily investing in biosimilar R&D and manufacturing.
• Global opportunity: With several blockbuster biologics losing patent protection by 2030, Indian companies are set to capitalise on the $100+ billion global biosimilars market.

B. Digital Health and Tech Integration

Technology is transforming healthcare delivery, and pharma is right in the middle of this shift.

• Telemedicine: Platforms like Practo, 1mg, and Apollo 24/7 are merging medicine, diagnostics, and e-pharmacy, enabling faster access to treatment and medication.
• Data-driven drug development: Companies are using AI and big data to streamline drug discovery, monitor clinical trials, and optimise supply chains.
• E-Pharmacy Boom: With rising smartphone penetration and government support, India’s e-pharmacy market is expected to grow at over 40% CAGR in the next few years.
• Investor takeaway: Pharma companies integrating tech or partnering with health-tech platforms are likely to see higher scalability and consumer stickiness.

C. Global Collaborations and Strategic Licensing

Indian pharma is increasingly seen as a strategic partner for global pharmaceutical giants.

• Out-licensing and co-development: Indian companies are signing deals to co-develop molecules, especially in oncology and chronic therapy segments.
• Contract Development and Manufacturing (CDMO): Firms like Suven Pharma and Neuland Labs are leveraging global demand to become key CDMO players.
• Access to global markets: Collaborations help Indian companies fast-track product launches, enter new geographies, and navigate regulatory pathways with ease.
• Example: In 2023, Biocon entered into a licensing agreement with Serum Institute and Viatris for vaccine and biosimilar distribution, opening multi-continent revenue streams.

You may also want to know the Best Paper Stocks in India for 2025

Risks to Consider Before Investing

While the Indian pharmaceutical sector holds significant long-term promise, it’s crucial to understand the risks that can impact stock performance. Pharma stocks often seem “defensive,” but they are not immune to external pressures, particularly on the global stage.

Regulatory Scrutiny

• Why it matters: Indian pharma companies export heavily to regulated markets like the US, EU, and Japan, where drug quality, manufacturing processes, and compliance standards are extremely strict.
• FDA inspections: The USFDA regularly audits Indian facilities. Observations (Form 483s), warning letters, import alerts, or bans can halt production or exports from certain plants.
• Impact: Regulatory issues can lead to temporary shutdowns, delays in product launches, and loss of investor confidence, often triggering stock price dips.
• Example: In the past, companies like Sun Pharma, Lupin, and Aurobindo have faced compliance issues leading to significant corrections in stock price.

Currency Fluctuation

• Why it matters: A large chunk of revenue for Indian pharma companies comes from exports, especially to the US and Europe. This means earnings are often in USD or EUR.
• Volatility: Fluctuations in the INR against the USD can impact profitability, especially if hedging strategies are not effectively in place.
• Double impact: While a weakening rupee may benefit exporters, currency volatility makes forecasting and planning difficult for both companies and investors.

Pricing Pressure in the US Generics Market

• Highly competitive market: The US generic market is witnessing intense competition, leading to price erosion.
• GPO dominance: The market is dominated by a few large Group Purchasing Organisations (GPOs), who push for aggressive pricing, squeezing margins.
• Patent cliffs & volume growth: Companies are often forced to take volume growth at the cost of pricing power, impacting overall profitability.
• Impact: Companies with high US exposure like Cipla, Dr. Reddy’s, and Zydus may face revenue headwinds due to this pricing pressure.

Dependence on China for APIs

• Historical dependence: A large percentage of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) used by Indian pharma companies have been imported from China.
• Geopolitical risk: Any disruptions due to geopolitical tensions, COVID-like lockdowns, or export restrictions from China can impact the supply chain and raise input costs.
• Current progress: India is reducing dependency through schemes like PLI and domestic API park development, but the transition is gradual and will take time.
• Investor lens: Watch for companies actively investing in backward integration and domestic API manufacturing; they will be more insulated from this risk.

Pharma Sector Outlook for 2025

The Indian pharmaceutical sector is entering a golden phase of transformation, driven by innovation, policy support, and increasing global relevance. As we move through 2025, multiple structural growth drivers are aligning to accelerate momentum in pharma stocks in India.

1. Specialty and Complex Generics: The Next Frontier

• Indian companies are shifting from basic generics to specialty drugs and complex formulations, including injectables, ophthalmics, dermatology products, and transdermal patches.
• These offer higher margins and longer exclusivity periods, giving firms a competitive edge in global markets.
• Companies like Sun Pharma, Dr. Reddy’s, and Cipla are leading the charge in this space with robust pipelines and ANDA (Abbreviated New Drug Application) filings.

2. API Self-Sufficiency: Reducing China Dependence

• With government support through the PLI scheme, Indian pharma companies are aggressively investing in API parks, domestic manufacturing units, and backward integration.
• This not only enhances supply chain security but also boosts operating margins by reducing import costs.
• Players like Divi’s Labs and Laurus Labs are expected to benefit significantly due to their strong API capabilities and export orientation.

3. Expansion into Emerging and Regulated Markets

• Indian pharma companies are increasingly tapping into high-growth emerging markets in Africa, Latin America, and Southeast Asia while also strengthening their base in regulated markets like the US and EU.
• Strategic acquisitions, joint ventures, and local partnerships are enabling companies to diversify revenues and reduce concentration risk.
• Brands like Lupin and Aurobindo are actively pursuing this multi-market strategy to de-risk and expand globally.

4. Biotech, Biosimilars & AI-Driven R&D

• Indian pharma is transitioning from volume-based growth to value-driven innovation. Biosimilars and biologics are gaining prominence due to patent expiries of blockbuster biologics globally.
• Companies like Biocon, Zydus, and Dr. Reddy’s are investing heavily in biosimilars and novel biologics, capturing new market share in high-value segments.
• Additionally, AI and machine learning are being integrated into drug discovery, clinical trials, and patient monitoring, cutting down R&D time and cost.

Analyst & Market Sentiment

• According to leading brokerages, the Nifty Pharma Index is expected to outperform the broader indices in the coming 12–24 months, driven by strong earnings visibility, export tailwinds, and policy support.
• Sectors like healthcare diagnostics, CDMOs (Contract Development and Manufacturing Organisations), and digital health are likely to see faster adoption and investor interest.

Conclusion

India’s pharmaceutical sector is no longer just a defensive play; it’s evolving into a dynamic, innovation-led growth engine. With robust global demand, policy support, shifting supply chains, and rising investments in biotech and digital health, pharma stocks in India are well-positioned to deliver strong long-term returns.

Whether you’re a conservative investor seeking stability through large caps or a risk-taker exploring small caps and pharma penny stocks, the sector offers a wide spectrum of opportunities. However, it’s equally crucial to be mindful of regulatory risks, pricing pressures, and global volatility.

At Jainam Broking, we help investors navigate such evolving sectors with insightful research and curated investment ideas.

So, are you planning on trading in the stock market? If yes, you are at the right place! 

Open a Demat Account with Jainam Broking Ltd. Now!